These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 21665991)
1. Mutant Atp13a2 proteins involved in parkinsonism are degraded by ER-associated degradation and sensitize cells to ER-stress induced cell death. Ugolino J; Fang S; Kubisch C; Monteiro MJ Hum Mol Genet; 2011 Sep; 20(18):3565-77. PubMed ID: 21665991 [TBL] [Abstract][Full Text] [Related]
2. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism. Park JS; Mehta P; Cooper AA; Veivers D; Heimbach A; Stiller B; Kubisch C; Fung VS; Krainc D; Mackay-Sim A; Sue CM Hum Mutat; 2011 Aug; 32(8):956-64. PubMed ID: 21542062 [TBL] [Abstract][Full Text] [Related]
3. Common pathogenic effects of missense mutations in the P-type ATPase ATP13A2 (PARK9) associated with early-onset parkinsonism. Podhajska A; Musso A; Trancikova A; Stafa K; Moser R; Sonnay S; Glauser L; Moore DJ PLoS One; 2012; 7(6):e39942. PubMed ID: 22768177 [TBL] [Abstract][Full Text] [Related]
4. Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2. Park JS; Sue CM Curr Protein Pept Sci; 2017; 18(7):725-732. PubMed ID: 26965689 [TBL] [Abstract][Full Text] [Related]
5. Regulation of intracellular manganese homeostasis by Kufor-Rakeb syndrome-associated ATP13A2 protein. Tan J; Zhang T; Jiang L; Chi J; Hu D; Pan Q; Wang D; Zhang Z J Biol Chem; 2011 Aug; 286(34):29654-62. PubMed ID: 21724849 [TBL] [Abstract][Full Text] [Related]
6. ATP13A2/PARK9 regulates endo-/lysosomal cargo sorting and proteostasis through a novel PI(3, 5)P2-mediated scaffolding function. Demirsoy S; Martin S; Motamedi S; van Veen S; Holemans T; Van den Haute C; Jordanova A; Baekelandt V; Vangheluwe P; Agostinis P Hum Mol Genet; 2017 May; 26(9):1656-1669. PubMed ID: 28334751 [TBL] [Abstract][Full Text] [Related]
7. Novel mutations in ATP13A2 associated with mixed neurological presentations and iron toxicity due to nonsense-mediated decay. Kırımtay K; Temizci B; Gültekin M; Yapıcı Z; Karabay A Brain Res; 2021 Jan; 1750():147167. PubMed ID: 33091395 [TBL] [Abstract][Full Text] [Related]
8. Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II). Fujita E; Kouroku Y; Isoai A; Kumagai H; Misutani A; Matsuda C; Hayashi YK; Momoi T Hum Mol Genet; 2007 Mar; 16(6):618-29. PubMed ID: 17331981 [TBL] [Abstract][Full Text] [Related]
9. α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9). Daniel G; Musso A; Tsika E; Fiser A; Glauser L; Pletnikova O; Schneider BL; Moore DJ Neurobiol Dis; 2015 Jan; 73():229-43. PubMed ID: 25461191 [TBL] [Abstract][Full Text] [Related]
10. Altered apoptosis regulation in Kufor-Rakeb syndrome patients with mutations in the ATP13A2 gene. Radi E; Formichi P; Di Maio G; Battisti C; Federico A J Cell Mol Med; 2012 Aug; 16(8):1916-23. PubMed ID: 22117566 [TBL] [Abstract][Full Text] [Related]
12. Ubiquilin and p97/VCP bind erasin, forming a complex involved in ERAD. Lim PJ; Danner R; Liang J; Doong H; Harman C; Srinivasan D; Rothenberg C; Wang H; Ye Y; Fang S; Monteiro MJ J Cell Biol; 2009 Oct; 187(2):201-17. PubMed ID: 19822669 [TBL] [Abstract][Full Text] [Related]
13. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Ramirez A; Heimbach A; Gründemann J; Stiller B; Hampshire D; Cid LP; Goebel I; Mubaidin AF; Wriekat AL; Roeper J; Al-Din A; Hillmer AM; Karsak M; Liss B; Woods CG; Behrens MI; Kubisch C Nat Genet; 2006 Oct; 38(10):1184-91. PubMed ID: 16964263 [TBL] [Abstract][Full Text] [Related]
14. Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants. Covy JP; Waxman EA; Giasson BI J Neurosci Res; 2012 Dec; 90(12):2306-16. PubMed ID: 22847264 [TBL] [Abstract][Full Text] [Related]
15. ATP13A2 deficiency induces a decrease in cathepsin D activity, fingerprint-like inclusion body formation, and selective degeneration of dopaminergic neurons. Matsui H; Sato F; Sato S; Koike M; Taruno Y; Saiki S; Funayama M; Ito H; Taniguchi Y; Uemura N; Toyoda A; Sakaki Y; Takeda S; Uchiyama Y; Hattori N; Takahashi R FEBS Lett; 2013 May; 587(9):1316-25. PubMed ID: 23499937 [TBL] [Abstract][Full Text] [Related]
16. Zn²⁺ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Tsunemi T; Krainc D Hum Mol Genet; 2014 Jun; 23(11):2791-801. PubMed ID: 24334770 [TBL] [Abstract][Full Text] [Related]
17. The Parkinson-associated human P5B-ATPase ATP13A2 modifies lipid homeostasis. Marcos AL; Corradi GR; Mazzitelli LR; Casali CI; Fernández Tome MDC; Adamo HP; de Tezanos Pinto F Biochim Biophys Acta Biomembr; 2019 Oct; 1861(10):182993. PubMed ID: 31132336 [TBL] [Abstract][Full Text] [Related]
18. Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove. Dehay B; Martinez-Vicente M; Ramirez A; Perier C; Klein C; Vila M; Bezard E Autophagy; 2012 Sep; 8(9):1389-91. PubMed ID: 22885599 [TBL] [Abstract][Full Text] [Related]
19. ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome. Grünewald A; Arns B; Seibler P; Rakovic A; Münchau A; Ramirez A; Sue CM; Klein C Neurobiol Aging; 2012 Aug; 33(8):1843.e1-7. PubMed ID: 22296644 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of human Atp13a2Isoform-1 protein protects cells against manganese and starvation-induced toxicity. Ugolino J; Dziki KM; Kim A; Wu JJ; Vogel BE; Monteiro MJ PLoS One; 2019; 14(8):e0220849. PubMed ID: 31393918 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]